Fagron N.V (FAGR.BR,ARSUF) Thursday said that its first quarter revenue rose 10.3 percent, helped by higher M&A contribution and a good performance in the Latin America region. Additionally, the company also provided outlook for the year ahead.
The Belgian pharmaceutical company reported revenue of 263.38 million euros in the first quarter of 2026, higher than 238.73 million euros in the same period last year. On a Constant Exchange Rate or CER basis, the increase in first quarter revenue was 15.0 percent.
Among regions, Latin America recorded a 39 percent rise in first quarter revenue to 57.23 million euros from 42.46 million euros a year ago. EMEA region's revenue also climbed 14.7 percent from the first quarter in 2025.
Looking ahead, the company provided fiscal 2026 outlook of mid-to-high single digit organic sales growth at CER, with a REBITDA margin of approximately 20 percent, helped by the Pharmavit acquisition.
On the Brussels Exchange, FAGR.BR ended Wednesday's trading at 22.15 euros, up 0.15 euros or 0.68 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.